A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Allergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection

"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."

Trial Locations (1)

96814

East West Medical Research Institute, Honolulu

Sponsors
All Listed Sponsors
lead

Immunomic Therapeutics, Inc.

INDUSTRY